Furthermore, a better understanding of the endogenous cytotoxic profiles in patients with T1D and other autoimmune diseases would be also valuable in order to anticipate the effect of IL-2 treatment in future clinical trials. This evidence concerns the gene IL2 and autoimmune disease.